The administration of miR-200b promoted tumor regression in vivo and abolished the maintenance of TGF-β-related EMT in AP-2α-and MAPK7-dependent manner in CCA (Fig. 6). The gene discussed is TGFB1; the disease is cholangiocarcinoma.